Generic name · Chemotherapy / Immunotherapy
Pembrolizumab J-Code / HCPCS Code
In short
Pembrolizumab is billed under HCPCS J9271 — Injection, pembrolizumab, 1 mg. One billing unit is 1 mg.
Reference
- Code
- J9271 — Injection, pembrolizumab, 1 mgMed-Code curated
- Billing unit
- 1 mg
- Same code in the directory
- Keytruda
- Pharmacologic class
- Programmed Death Receptor-1 Blocking Antibody; EndoglycosidaseFrom the FDA listings below
- Labelers
- Merck Sharp & Dohme LLC
- J-code category
- Chemotherapy / Immunotherapy
FDA-listed products
Finished products whose name and route match this directory entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Keytrudapembrolizumab | Pembrolizumab 25 mg/mL | Injection, SolutionIntravenous | Merck Sharp & Dohme LLC | 0006-3026 |
Other products with this name
Same name but a different route, formulation or combination — the code above does not apply to these.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Keytruda Qlexpembrolizumab and berahyaluronidase alfa-pmph | Pembrolizumab 165 mg/mL; Berahyaluronidase alfa 2000 U/mL | Injection, SolutionSubcutaneous | Merck Sharp & Dohme LLC | 0006-3083 |
| Keytruda Qlexpembrolizumab and berahyaluronidase alfa-pmph | Pembrolizumab 165 mg/mL; Berahyaluronidase alfa 2000 U/mL | Injection, SolutionSubcutaneous | Merck Sharp & Dohme LLC | 0006-5083 |
NDCs billed under J9271
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 2 NDCs to J9271 for Keytruda. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Keytruda | 00006-3026-02 | Merck Sharp & Dohme LLC | 4 | 100 |
| Keytruda | 00006-3026-04 | Merck Sharp & Dohme LLC | 2 × 4 | 200 |